Marco Polo Peralta Álvarez

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2020 · 5K citations · Full text

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley et al. · The Lancet · 2020 · 2.6K citations · Full text

Vaccination, Vaccine Safety, Phase 1/2 +7

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2021 · 1.2K citations · Full text

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Amy Flaxman, Natalie G. Marchevsky, Daniel Jenkin et al. · The Lancet · 2021 · 253 citations · Full text

Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer

Óscar Arrieta, Feliciano Barrón, Zyanya Lucía Zatarain-Barrón et al. · JAMA Oncology · 2020 · 149 citations · Full text